Despite major industry investment, sterile fill-finish capacity remains constrained across Europe.
The continued growth of injectable biologics, GLP-1 therapies, monoclonal antibodies, and advanced therapeutics has significantly increased demand for aseptic manufacturing capacity.
At the same time, Annex 1 implementation across Europe is increasing operational and compliance pressure on manufacturers.
Key Drivers:
- Growth in injectable biologics
- Increasing demand for prefilled syringes and cartridges
- Annex 1 compliance requirements
- Growth of personalized medicine
- Expansion of clinical biologics pipelines
CDMOs Expanding Fill-Finish Infrastructure:
- Vetter
- Recipharm
- Baxter BioPharma Solutions
- Fareva
- IDT Biologika
- Catalent
- Thermo Fisher Scientific
- Siegfried
- Aenova
- Sharp Services
What This Means for Sponsors
Securing fill-finish capacity early is becoming increasingly critical for biologics developers. Sponsors are entering long-term manufacturing agreements earlier in development to avoid future commercial bottlenecks.
